Axonics, Inc.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and u…
Medical - Devices
US, Irvine [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Axonics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2018 | - | -1.588 | - | 0.34 | - | -77 | - | 0.13 | - | 0.14 | - | 0.53 |
| 2019 | -4.6400 | -2.769 | 0.71 | 14 | -32 | -135 | -31 | -5 | -32 | -5 | 13 | 21 |
| 2020 | -2.8000 | -1.512 | 13 | 112 | -79 | -66 | -77 | -62 | -80 | -65 | 67 | 111 |
| 2021 | -1.4800 | -1.892 | 111 | 177 | -54 | -71 | -52 | -56 | -53 | -65 | 91 | 132 |
| 2022 | -1.8600 | -1.533 | 180 | 269 | -80 | -91 | -60 | -81 | -67 | -94 | 138 | 204 |
| 2023 | -1.2800 | -0.100 | 273 | 363 | -59 | -1 | -27 | -89 | -42 | -104 | 196 | 224 |
| 2024 | -0.1200 | 0.212 | 366 | 450 | -6 | 10 | 8 | -169 | -4 | -184 | 235 | 707 |
| 2025 | - | 0.860 | - | 539 | - | 42 | - | -203 | - | -221 | - | 847 |
| 2026 | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F8X/td> | - | 2.F81/td> | - | 2.F81 | - | 2.F81 |
| 2027 | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F9X/td> | - | 1.F91/td> | - | 1.F91 | - | 1.F91 |
| 2028 | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F10X/td> | - | 0.F101/td> | - | 0.F101 | - | 0.F101 |